PledPharma AB has completed a clinical trial in colon cancer patients going through chemotherapy.
The study is designed to find out whether pre-treatment with the PLEDderivative PP-095 lowers the frequency and severity of adverse events during adjuvant chemotherapy according to the FOLFOX6 regimen in patients operated for colon cancer in stage Dukes’ C. Preclinical research has shown that PP-095 protects normal tissues without loss of anti-cancer activity during chemotherapy.
The study group, headed by professor Ursula Falkmer at the Oncology Department, Ryhov Hospital, will start analyzing the results from the trial and expect to finalize a study report by mid June (2010).
“I am pleased that we have completed the trial and look forward to see the results”, says assistant professor Jan Olof G. Karlsson, chief scientific officer in PledPharma.
For further information, please contact:
Jan Olof G. Karlsson, Chief Scientific Officer, PledPharma AB, +46 733 304 624
PledPharma AB develops new medicines based on Low Molecular weight Enzyme Mimetics (LowMEM) with an initial candidate PP-095 for oncology. PP-095 protects against dose-limiting side effects during cancer therapy with cytostatic drugs, without diminishing the anticancer effect. PP-095 entered clinical phase II trials in cancer patients in 2008. In addition to cancer treatment, LowMEMs have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.
For more information see www.pledpharma.se